Bosch Pharmaceuticals (Pvt) Ltd.
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi-based pharmaceutical manufacturer with multiple production plants and a broad local and export portfolio.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Bosch Pharmaceuticals (Pvt) Ltd
- Company type
- Private pharmaceutical manufacturer
- Address
- 8, Modern Society, Tipu Sultan Road, Karachi-75350, Pakistan · 75350
- Website
- bosch-pharma.com ↗
- Phone
- +92 21 111 126 724
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Maladrin | Sulfadoxine + Pyrimethamine | 500 mg + 25 mg | Tablet | 2's | 017655 | PKR 15.53 | PKR 7.77/tablet | 18% below median |
| Maladrin + | Sulfadoxine + Pyrimethamine | 500 mg + 25 mg | Tablet | 10's | 017655 | PKR 85.14 | PKR 8.51/tablet | 8% below median |
| Penro | Meropenem | 500 mg | Injection | 1’s | 042106 | PKR 2,077.40 | PKR 2,077.40/vial/unit | Near median |
| Penro | Meropenem | 1000 mg | Injection | 1’s | 042107 | PKR 3,883.01 | PKR 3,883.01/vial/unit | 6% below median |
| Qilox | Ciprofloxacin | 200 mg/100 mL | IV infusion | 1's | 070609 | PKR 221.59 | PKR 221.59/vial/unit | 7% above median |
| Qilox | Ciprofloxacin | 400 mg/100 mL | IV infusion | 1's | 073415 | PKR 304.68 | PKR 304.68/vial/unit | 12% below median |
| Qilox | Ciprofloxacin | 100 mg/50 mL | IV infusion | 1's | 073416 | PKR 66.48 | PKR 66.48/vial/unit | 38% below median |
| Qmetem + | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 050506 | PKR 621.28 | PKR 38.83/tablet | Near median |
| Qmetem Plus DS | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6’s | 067515 | PKR 640.69 | PKR 106.78/tablet | Near median |
| Qmetem-DS + | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8’s | 061699 | PKR 504.79 | PKR 63.10/tablet | Near median |
| Qmetem-P | Artemether | 80 mg/mL | Injection | 5’s × 1ml | 055640 | PKR 931.92 | PKR 186.38/mL | Near median |
| Quinbos | Chloroquine | 250 mg | Tablet | 50 x 10's | 112510 | PKR 509.62 | PKR 1.02/tablet | 35% below median |
| Quinbos-H | Hydroxychloroquine | 200 mg | Tablet | 5 x 10's | 112509 | PKR 594.11 | PKR 11.88/tablet | 18% below median |
| Quinbos-H | Hydroxychloroquine | 200 mg | Tablet | 30's | 112509 | PKR 356.47 | PKR 11.88/tablet | 18% below median |
| Quinoflox | Ciprofloxacin | 500 mg | Tablet | 10's | 015919 | PKR 647.69 | PKR 64.77/tablet | 52% above median |
| Quinoflox | Ciprofloxacin | 250 mg | Tablet | 10's | 015930 | PKR 367.99 | PKR 36.80/tablet | 44% above median |
| Quinoflox | Ciprofloxacin | 100 mg/50 mL | IV infusion | 50ml | 023020 | PKR 456.80 | PKR 9.14/mL | 285% above median |
| Quinoflox | Ciprofloxacin | 200 mg/100 mL | IV infusion | 100ml | 023021 | PKR 522.23 | PKR 5.22/mL | 132% above median |
| Quinoflox | Ciprofloxacin | 0.3% w/v (3 mg/mL) | Ophthalmic drops | 1's | 026622 | PKR 175.43 | PKR 175.43/unit | No comparator |
| Quinoflox | Ciprofloxacin | 100 mg | Tablet | 10's | 037632 | PKR 97.07 | PKR 9.71/tablet | Near median |
| Quinoflox | Ciprofloxacin | 750 mg | Tablet | 10's | 037633 | PKR 349.47 | PKR 34.95/tablet | 13% below median |
| Quinoflox | Ciprofloxacin | 400 mg/200 mL | IV infusion | 200ml 1's | 039583 | PKR 326.17 | — | No comparator |
| Quinoflox | Ciprofloxacin | 400 mg/100 mL | IV infusion | 100ml 1’s | 048489 | PKR 320.35 | — | No comparator |
| Quinoflox | Ciprofloxacin | 250 mg/5 mL | Oral suspension | 60ml | 104090 | PKR 242.93 | PKR 4.05/mL | 12% below median |
| Qumic | Levofloxacin | 250 mg | Tablet | 10's | 023979 | PKR 621.28 | PKR 62.13/tablet | 28% above median |
| Qumic | Levofloxacin | 500 mg | Tablet | 10's | 023980 | PKR 1,164.90 | PKR 116.49/tablet | 47% above median |
| Qumic | Levofloxacin | 750 mg | Tablet | 10's | 050504 | PKR 407.71 | PKR 40.77/tablet | 56% below median |
| Qvir | Sofosbuvir | 400 mg | Tablet | 28's | 084648 | PKR 11,392.72 | PKR 406.88/tablet | 6% below median |
| Rilpir + | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 110182 | PKR 10,849.30 | PKR 90.41/tablet | 6% below median |
| Supramox | Amoxicillin | 0.25 g | Injection | 1's | 015904 | PKR 62.49 | PKR 62.49/vial/unit | No comparator |
| Supramox | Amoxicillin | 500 mg | Injection | 1's | 015905 | PKR 98.47 | PKR 98.47/vial/unit | 36% above median |
| Supramox | Amoxicillin | 0.5 g | Injection | 1's | 015905 | PKR 98.47 | PKR 98.47/vial/unit | No comparator |
| Supramox | Amoxicillin | 500 mg | Capsule | 20’s | 015921 | PKR 407.66 | PKR 20.38/capsule | Near median |
| Supramox | Amoxicillin | 500 mg | Capsule | 100's | 015921 | PKR 1,995.43 | PKR 19.95/capsule | Near median |
| Supramox | Amoxicillin | 250 mg | Capsule | 20’s | 015926 | PKR 225.83 | PKR 11.29/capsule | Near median |
| Supramox | Amoxicillin | 250 mg | Capsule | 100's | 015926 | PKR 1,129.16 | PKR 11.29/capsule | Near median |
| Supramox | Amoxicillin | 250 mg/5 mL | Suspension | 90ml | 015927 | PKR 202.67 | PKR 2.25/mL | Near median |
| Supramox | Amoxicillin | 250 mg/5 mL | Suspension | 60ml | 015927 | PKR 134.34 | PKR 2.24/mL | Near median |
| Supramox | Amoxicillin | 125 mg/5 mL | Suspension | 90ml | 016050 | PKR 136.66 | PKR 1.52/mL | Near median |
| Supramox | Amoxicillin | 125 mg/5 mL | Suspension | 60ml | 016050 | PKR 91.49 | PKR 1.52/mL | Near median |
| Supramox | Amoxicillin | 250 mg | Tablet | 10 × 10's | 034854 | PKR 483.43 | PKR 4.83/tablet | 27% below median |
| Supramox | Amoxicillin | 500 mg | Tablet | 10 × 10's | 034855 | PKR 873.68 | PKR 8.74/tablet | 44% below median |
| Supramox | Amoxicillin | 1000 mg | Tablet | 12's | 039184 | PKR 174.74 | PKR 14.56/tablet | 46% below median |
| Tanzo | Piperacillin + tazobactam | 4 g + 0.5 g | Injection | 1's | 039439 | PKR 1,292.61 | PKR 1,292.61/vial/unit | 18% below median |
| Tanzo | Piperacillin + tazobactam | 2 g + 0.250 g | Injection | 1's | 039593 | PKR 627.84 | PKR 627.84/vial/unit | No comparator |
| Tanzo | Piperacillin + tazobactam | 3 g + 0.375 g | Injection | 1's | 070870 | PKR 627.84 | PKR 627.84/vial/unit | No comparator |
| Tariflox | Ofloxacin | 0.3 % | Ophthalmic drops | 1's | 026623 | PKR 138.50 | PKR 138.50/unit | No comparator |
| Troz | Metronidazole | 500 mg/100 mL | IV infusion | 100ml | 034856 | PKR 189.93 | PKR 1.90/mL | Near median |
| Troz | Metronidazole | 200 mg | Tablet | 20 × 10's | 076563 | PKR 330.05 | PKR 1.65/tablet | 23% below median |
| Troz | Metronidazole | 400 mg | Tablet | 20 × 10's | 076564 | PKR 485.38 | PKR 2.43/tablet | 20% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.